Pancreatic ductal adenocarcinoma, Lung adenocarcinoma, Biliary tract adenocarcinoma, Urothelial bladder cancer research hub

Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours

This study is testing a new drug for certain advanced cancers, including some pancreatic, lung, and bile duct cancers. Doctors want to see how well the drug shrinks tumours and if it's safe. It's for adults whose cancer has a specific genetic change.